Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
Point32Health Chief Financial Officer Mike Marrone said the new coverage limits on GLP-1 drugs alone could contribute as much as $100 million or more in savings in 2026
Nagata, Y., Yamamoto, S
At Primary Care Center of Clear Lake, Dr
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a medication that mimics the natural GLP-1 hormone produced in the small intestine
Retatrutide (also identified by the compound code LY3437943) is an investigational peptide medicine being developed by Eli Lilly as a potential treatment for obesity and related metabolic conditions
Neuroscience 20 May 2026 Dihexa for CTE (Chronic Traumatic Encephalopathy): The 2026 UK Review Rigorous 2026 UK review of Dihexa for chronic traumatic encephalopathy (CTE)
US$ 25.56
US$ 26.08
US$ 23.68
US$ 21.16
